CK2—an emerging target for neurological and psychiatric disorders

Julia Castello, Andre Ragnauth, Eitan Friedman, Heike Rebholz

Research output: Contribution to journalReview articlepeer-review

Abstract

Protein kinase CK2 has received a surge of attention in recent years due to the evidence of its overexpression in a variety of solid tumors and multiple myelomas as well as its participation in cell survival pathways. CK2 is also upregulated in the most prevalent and aggressive cancer of brain tissue, glioblastoma multiforme, and in preclinical models, pharmacological inhibition of the kinase has proven successful in reducing tumor size and animal mortality. CK2 is highly expressed in the mammalian brain and has many bona fide substrates that are crucial in neuronal or glial homeostasis and signaling processes across synapses. Full and conditional CK2 knockout mice have further elucidated the importance of CK2 in brain development, neuronal activity, and behavior. This review will discuss recent advances in the field that point to CK2 as a regulator of neuronal functions and as a potential novel target to treat neurological and psychiatric disorders.

Original languageEnglish
Article number7
JournalPharmaceuticals
Volume10
Issue number1
DOIs
StatePublished - 1 Mar 2017
Externally publishedYes

Keywords

  • CK2
  • CK2 inhibitors
  • CK2 knockout
  • CK2 substrates
  • GPCRs
  • Neurodegeneration
  • Signaling
  • Synapse

Fingerprint

Dive into the research topics of 'CK2—an emerging target for neurological and psychiatric disorders'. Together they form a unique fingerprint.

Cite this